ACAD Jun 2021 43.000 call
- ACCESSWIRE
SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm
BOSTON, MA / ACCESSWIRE / March 8, 2021 / Block & Leviton LLP (www.com), a national securities litigation firm, announces that it is investigating Acadia Pharmaceuticals Inc.
- Business Wire
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company received a notification from the U.S. Food and Drug Administration (FDA) on March 3, 2021, stating that, as part of its ongoing review of the Company’s supplemental New Drug Application (sNDA), the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The FDA stated that the notification does not reflect a final decision on the information under review.
- Business Wire
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2020.
